Research · November 10, 2026

Ozlo's $22M Series B — From Sleep Earbuds to a Sleep Health Platform

Ozlo raised $22 million in a Series B led by Modi Ventures to expand beyond its Sleepbuds earbuds into sleep and nighttime health — including regulatory work to submit a tinnitus product to the FDA for review — as the company reports passing 260,000 customers in under two years.

What happened

On October 29, 2026, Ozlo, a Boston-based sleep technology company, announced a $22 million Series B financing led by Modi Ventures. Existing investors LifeArc, Artis Ventures, Resmed, Scrum Ventures, Drive by DraftKings, Wheelhouse 360, WISE Ventures, Niremia Collective, Accelerate Ventures, and World Solver Syndicate participated, along with individual investors including former NFL quarterback Nick Foles, Olympic snowboarder Danny Davis, Whole30 founder Melissa Urban, and performance psychologist Michael Gervais. One accounting detail matters for reading the headline: the announcement states that the round size includes previously issued convertible instruments, so the $22 million is not all newly issued cash.

The round arrives as Ozlo reports passing 260,000 customers in under two years. The stated use of funds is expansion in two directions at once: scaling the core Sleepbuds business globally and accelerating next-generation products, with increased investment across hardware, software, engineering, and research and development — and moving beyond Sleepbuds into new areas of sleep and nighttime health, including advancing the regulatory work required to submit a tinnitus product to the U.S. Food and Drug Administration (FDA) for review.

What Sleepbuds actually are

Ozlo Sleepbuds are earbuds designed for sleep rather than adapted to it: small, flush-fitting buds built for all-night comfort, including for side sleepers, that use intelligent noise masking to reduce nighttime disruptions such as snoring and city sounds. In July 2026, Ozlo launched Sleepbuds 2, the latest version of the flagship, featuring up to 14 hours of battery life, improved connectivity, and an upgraded audio system. Throughout 2025 and 2026, the company says, Ozlo earned recognition from TIME, Fast Company, CES, Men's Health, Sleepopolis, Sleep Foundation, Forbes, Oprah Daily, goop, and Harper's Bazaar UK.

The backstory explains why comfort is the company's first argument rather than an afterthought. Ozlo was founded in 2022 by former Bose engineers, building on the discontinued Bose Sleepbuds line through licensed technology — a lineage that matters because the hardest problem for a sleep wearable is not sound quality but wearability: a bud that hurts, slips out, or dies mid-night fails no matter how good its audio is. Modi Ventures founder Sahir Ali makes exactly that point in the announcement: “any wearable sleep technology must get comfort right first — without it, even the most advanced technology will struggle to gain adoption,” citing Ozlo's customer traction as evidence the company has cleared that bar.

Why the tinnitus move is the real story

The funding's most consequential line is not the Sleepbuds expansion but the regulatory one. Ozlo says it will advance the work required to submit a tinnitus product to the FDA for review — a step from consumer wellness into regulated clinical territory. That is a different kind of bet from selling more earbuds: it means building evidence and a submission package for a condition where sleep disruption is tied to an underlying health problem, rather than to a noisy bedroom.

The partnerships in the announcement sketch how that bridge is supposed to work. Ozlo cites an ongoing product collaboration and integration with Calm, collaborations with several major domestic and international research institutions, and partnerships with elite athletes and high-performance teams, including Canada Snowboard. Most notably, it is partnering with Dreem Health, a nationwide virtual sleep clinic, to give people a direct path from better sleep at home to expert clinical care — connecting Ozlo's technology with sleep specialists who can evaluate, diagnose, and treat common sleep disorders. The logic is a funnel: a consumer device people already wear at night becomes the front door to clinical sleep care, rather than a gadget that ends at the nightstand.

CEO N.B. Patil frames the ambition in category terms: “Ozlo Sleepbuds helped define a new category of technology designed specifically for sleep, and we're now building on that foundation to address a much broader range of sleep needs.” Ali's version of the same ambition is a platform one — evolving “into a transformative sleep health platform powered by biosensing, AI, and neuromodulation.” Both framings point the same way: the earbud is the wedge, not the destination.

Why this is a different bet from the other wearable story

This queue recently featured StimCardio, another wearable story — but the two bets run in opposite directions. StimCardio starts in the clinic: a therapeutic wrist wearable with a sham-controlled pilot, designed as an adjunct to catheter ablation, heading toward a De Novo submission for a specific cardiac indication. Ozlo starts in the consumer's bedroom: a comfort-first product with 260,000 customers, now reaching toward clinical territory from the other side, with tinnitus as the first regulatory test.

That distinction sets both the opportunity and the risk. Ozlo's distribution advantage is real — it already has a customer base that wears its product every night, and a device people tolerate is a prerequisite for any biosensing or neuromodulation ambition. But the clinical path is unproven in the announcement: there is no submission date, no clinical data, and no description of what the tinnitus product does or how it would be evaluated. A consumer brand that has won on comfort must now win on evidence, under FDA scrutiny, in a category where efficacy claims are policed rather than marketed.

What this does not show

The announcement discloses no valuation, revenue, or pricing figure, and no split between new cash and the previously issued convertible instruments included in the $22 million. It gives no timeline for the tinnitus product's FDA submission, no clinical evidence for it, and no detail on what the next-generation products are or when they arrive. The 260,000-customer figure is the company's own count, and the awards list is a recognition record, not a measure of clinical outcomes. The biosensing, AI, and neuromodulation platform language is an investor's framing of the ambition, not a shipped product specification.

What would turn this round from a consumer success story into a health platform is the tinnitus submission itself: a product that survives regulatory review and demonstrates, with evidence rather than comfort claims, that a device people already sleep in can also treat something that keeps them awake. Until then, Ozlo has the more proven half of the sleep pitch — a product hundreds of thousands of people actually wear all night — and the harder half still to prove: that comfort can be converted into clinical care.

---

Sources